Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Izanne Roos

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|October 19, 2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosisChao Zhu, Zhen Zhou, Izanne Roos, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2022
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registrySifat Sharmin, Charles B Malpas, Izanne Roos, et al.
Journal of Neurology|April 14, 2025
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort studyPakeeran Siriratnam, Saif Huda, Anneke Van der Walt, et al.
Neurology|November 19, 2024
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSDPakeeran Siriratnam, Saif Huda, Anneke Van Der Walt, et al.
CNS Drugs|February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational StudyJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Brain : a Journal of Neurology|June 10, 2026
Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosisCarmen Tur, Silvia Susin-Calle, Susana Otero-Romero, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 28, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 yearsJodie I Roberts, Sifat Sharmin, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
Neurology|March 5, 2026
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum DisorderPakeeran Siriratnam, Vilija G Jokubaitis, Anneke Van Der Walt, et al.
JAMA Neurology|June 12, 2023
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Stella Hughes, Gavin McDonnell, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Journal of Neurology, Neurosurgery, and Psychiatry|October 19, 2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosisChao Zhu, Zhen Zhou, Izanne Roos, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2022
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registrySifat Sharmin, Charles B Malpas, Izanne Roos, et al.
Journal of Neurology|April 14, 2025
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort studyPakeeran Siriratnam, Saif Huda, Anneke Van der Walt, et al.
Neurology|November 19, 2024
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSDPakeeran Siriratnam, Saif Huda, Anneke Van Der Walt, et al.
CNS Drugs|February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational StudyJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Brain : a Journal of Neurology|June 10, 2026
Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosisCarmen Tur, Silvia Susin-Calle, Susana Otero-Romero, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 28, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 yearsJodie I Roberts, Sifat Sharmin, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
Neurology|March 5, 2026
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum DisorderPakeeran Siriratnam, Vilija G Jokubaitis, Anneke Van Der Walt, et al.
JAMA Neurology|June 12, 2023
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Stella Hughes, Gavin McDonnell, et al.
Pageof 8